Early tumor shrinkage and depth of response predict long-term outcome in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab: results from phase III TRIBE trial by the Gruppo Oncologico del Nord Ovest

摘要: ABSTRACT Background Early tumor shrinkage (ETS) and depth of response (DoR) predict overall survival (OS) in first-line trials chemotherapy ± anti-EGFR monoclonal antibodies metastatic colorectal cancer (mCRC). These associations the predictive accuracy measurements for parameters were investigated phase III TRIBE trial FOLFOXIRI plus bevacizumab (bev) versus FOLFIRI bev. Patients methods A landmark approach was adopted to define assessable population. The distribution RECIST rate, ETS DoR compared two arms. Associations between progression-free (PFS), post-progression (PPS) OS tested by univariate multivariate Cox models. Prediction performance each factor estimated C-index. Results significantly higher percentage patients bev arm achieved ≥20%, when with control (62.7% 51.9%, P = 0.025). Also triplet (43.4% 37.8%, 0.003). Both associated PFS, PPS at analyses models stratified other prognostic variables. able as accurately response. Conclusion improves Achieving rapid deep consistently delays progression prolongs treated is a promising valuable end point clinical trials' design deserving further investigation.